Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus

Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis

(2016) Otavio Cabral-Marques et al.   AUTOIMMUNITY REVIEWS

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

A volcanic explosion of autoantibodies in systemic lupus erythematosus: A diversity of 180 different antibodies found in SLE patients

(2015) Gal Yaniv et al.   AUTOIMMUNITY REVIEWS

Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus

(2015) Christopher M Tipton et al.   NATURE IMMUNOLOGY

Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells

(2015) Emma M. Carrington et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells

(2015) William Stohl   Arthritis & Rheumatology

Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension

(2015) Li Guo et al.   Arthritis & Rheumatology

Bcl-2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus-Prone Mice and Dampen Interferon-α Production

(2015) Yifan Zhan et al.   Arthritis & Rheumatology

The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis

(2014) J. Xiong et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Systemic lupus erythematosus

(2014) Larissa Lisnevskaia et al.   LANCET

Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199

(2014) S L Khaw et al.   LEUKEMIA

Many players in BCL-2 family affairs

(2014) Tudor Moldoveanu et al.   TRENDS IN BIOCHEMICAL SCIENCES

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Mechanisms of B cell autoimmunity in SLE

(2011) Thomas Dörner et al.   ARTHRITIS RESEARCH & THERAPY

The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus

(2010) Bernadete L. Liphaus et al.   Clinics

CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients

(2010) Paul A. Blair et al.   IMMUNITY

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes

(2009) Q.-Z. Li et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE

(2008) Matilda W. Nicholas et al.   CLINICAL IMMUNOLOGY

The innate immune system in SLE: type I interferons and dendritic cells

(2008) L Rönnblom et al.   LUPUS